Research Training in Pediatric Oncology

描述（由申请人提供）：这是一个新的培训补助金支持申请，具有单一使命：该T32计划的目标是培训医生，他们将成为基础和/或临床儿科肿瘤学研究的未来学术领导者。减少儿科人群的癌症负担需要从基础分子和细胞生物学研究到转化工作的整个范围的研究，这些研究弥合了基础研究和临床医学到临床研究的鸿沟。减少儿科人群的癌症负担需要对学术儿科医生进行广泛而深入的培训。一个经验丰富和高度成就的教师小组，包括达纳法伯癌症研究所（DFCI）儿科肿瘤学系的教师，波士顿儿童医院（CHB）儿科血液学/肿瘤学部门，以及哈佛医学院的其他组成部分构成了该计划的培训教师。该学院包括基础，翻译和临床研究。受训人员将从DFCI-CHB儿科血液学/肿瘤学联合奖学金计划中选择。特别强调在选择导师和在研究期间持续监督时对学员的密切指导。该计划致力于识别和支持最有前途的研究员，包括少数民族候选人。在过去的40年里，DFCI-CHB奖学金计划已经培训了超过200人，其中许多人是领导者和学术儿科医学。拟议的T32计划将确保奖学金计划的持续和进一步发展，并承诺为癌症儿童的管理做出不可估量的贡献。 虽然在儿科癌症的诊断和治疗方面取得了很大进展，但仍有许多工作要做。患者的治愈通常伴随着不可接受的副作用，并且对于许多实体瘤，目前的治疗是不足的。减少儿童癌症负担的最大希望是由经验丰富和有成就的教师培训致力于研究人员，这些教师参与与解决儿童这些具有挑战性的问题直接相关的基础和临床研究的各个方面。

DESCRIPTION (provided by applicant): This is a new application for training grant support with a single mission: the goal of this T32 program is to train physicians who will be the future academic leaders in basic and/or clinical pediatric oncology research. Reducing the burden of cancer in the pediatric population requires necessitates research across the entire spectrum from fundamental molecular and cellular biologic studies to translational work that bridges the gulf that separates basic research and clinical medicine to clinical investigation. Reducing the burden of cancer in pediatric populations requires broad and intensive training of academic pediatric physicians. An experienced and highly accomplished group of faculty including faculty of the Department of Pediatric Oncology at the Dana Farber Cancer Institute (DFCI), the Division of Pediatric Hematology/Oncology at Children's Hospital Boston (CHB), and additional components of the Harvard Medical School constitute the training faculty for this program. This faculty encompasses basic, translational, and clinical investigation. Trainees will be selected from the combined DFCI-CHB pediatric hematology/oncology fellowship program. Particular emphasis is placed on close mentorship of trainees in the selection of mentors and in on-going oversight during their research. The program is committed to identifying and supporting the most promising fellows, including minority candidates. Over the past 40 years the DFCI-CHB fellowship program has trained >200 individuals, many of whom are leaders and academic pediatric medicine. The proposed T32 program will ensure the continuance and further development of the fellowship program, and promises to contribute immeasurably to the management of children with cancer. While great strides have been made in diagnosis and treatment of pediatric cancers, much remains to be done. Cure of patients is often achieved with unacceptable side-effects, and for many solid tumors current therapy is inadequate. The best hope for reducing the burden of pediatric cancer is the training of committed researchers by an experienced and accomplished faculty that is involved in diverse aspects of basic and clinical research directly relevant to tackling these challenging problems in children.